CYTUNEPHARMA
Cytune is a private company developing a broad portfolio of novel immunotherapeutic agents to treat primarily cancer. Cytune’s hedge relies on a proprietary scientific breakthrough in immunology: effective form of a major human immunocytokine: trans-presentation mechanism of a critical immune factor: IL-15 Cytune’s proprietary most advanced proprietary compound, CYP 0150, is a human interleukin-15 uniquely linked to its effector. Cytune is further developing conjugated monoclonal antibodies linked to CYP 0150. Cytune was founded in 2007 and is managed by Dr. David Bechard, a successful serial biotech entrepreneur and Dr. Yannick Jacques, Director of Public Research at the Inserm (National Institute for Health and Medical Research)
CYTUNEPHARMA
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2007-01-01
Address:
Nantes, Pays De La Loire, France
Country:
France
Website Url:
http://www.cytunepharma.com
Total Employee:
1+
Status:
Active
Contact:
+33 2 40 08 47 23
Total Funding:
6.66 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
DataHow
DataHow offers digital solutions and consulting for process screening, monitoring, optimization, control and scale-up.
Exponential Biotherapies
Exponential Biotherapies develops therapeutics to attenuate overreactions of the immune system.
Current Employees Featured
Founder
Investors List
PPF Group
PPF Group investment in Venture Round - CytunePharma
PPF Group
PPF Group investment in Venture Round - CytunePharma
ABAB (Atlantic Business Angels Booster)
ABAB (Atlantic Business Angels Booster) investment in Venture Round - CytunePharma
Official Site Inspections
http://www.cytunepharma.com
- Host name: unassigned-ip.savana.cz
- IP address: 185.183.11.92
- Location: Czechia
- Latitude: 50.0848
- Longitude: 14.4112
- Timezone: Europe/Prague
More informations about "CytunePharma"
SOTIO and PPF complete acquisition of Cytune Pharma
Aug 30, 2018 Cytune Pharma develops IL-15 based therapies for the treatment of cancer. The lead molecule of Cytune’s pipeline, SO-C101 (RLI-15), is a human fusion protein of IL-15 and …See details»
Sotio acquires CytunePharma - 2018-08-30 - Crunchbase
CytunePharma Cytune’s goal is to turn novel concepts into best-in class immunotherapeutics restoring and activating the immune system to fight cancer. Acquiring Organization: Sotio …See details»
Cytune Pharma - PitchBook
Cytune Pharma General Information Description. Developer of immunotherapeutic agents in France. The company specializes in the in research and development of immunotherapies, whose properties allow the restoration …See details»
Cytune Pharma - LinkedIn
Cytune Pharma, a biotechnology company owned by PPF Group, is responsible for the clinical development of SO-C101, SOTIO is a sponsor of the Phase 1 clinical trial ...See details»
Cytune Pharma SAS - Company Profile and News - Bloomberg …
Company profile page for Cytune Pharma SAS including stock price, company news, executives, board members, and contact informationSee details»
CytunePharma - Funding, Financials, Valuation & Investors
Cytune’s goal is to turn novel concepts into best-in class immunotherapeutics restoring and activating the immune system to fight cancer.See details»
PPF Group acquires a minority stake in biotech company Cytune …
Cytune Pharma is a private company dedicated to the research and development of a portfolio of novel immunotherapeutic agents which expand and activate immune responses to treat …See details»
CytunePharma - Company Profile - Tracxn
Nov 5, 2024 CytunePharma - Developing immunostimulatory agents (interleukin-15) & conjugated mAbs for cancer. Raised a total funding of $11.6M over 4 rounds from 5 investors. …See details»
Cytune Pharma SAS - life-sciences-europe.com
Jan 1, 2007 Cytune Pharma leverages the transpresentation mechanism of the critical immune factor, IL-15, by the IL-15Rachain thanks to the development of a proprietary scientific …See details»
CytunePharma - Tech Stack, Apps, Patents & Trademarks
Cytune’s goal is to turn novel concepts into best-in class immunotherapeutics restoring and activating the immune system to fight cancer.See details»
CytunePharma Company Information - Funding, Investors, and …
Get information on funding, investors, industries, and more for CytunePharma. See CytunePharma company profile and funding data.See details»
CytunePharma - VentureRadar
Jul 10, 2016 Mirabilis is dedicated to improving the treatment of symptomatic uterine fibroids using its proprietary high-intensity focused ultrasound (HIFU) technology.See details»
Cytune Pharma - Products, Competitors, Financials, Employees ...
For instance, SOTIO had acquired Cytune Pharma to allow the company the usage of Cytune’s SO-C101 in 2018. In January 2020, Coherus BioSciences, Inc. entered into a licensing …See details»
SOTIO - PMC - National Center for Biotechnology Information
SOTIO's affiliated company - Cytune Pharma, a French biotechnology company focuses on the development of a modified IL-15 (RLI) acting as a potent stimulant of NK cells and cytotoxic T …See details»
CytunePharma - Crunchbase
Cytune’s goal is to turn novel concepts into best-in class immunotherapeutics restoring and activating the immune system to fight cancer.See details»
Cytune Pharma secures €6M in financing to advance lead im...
Nantes, June 29, 2016 – Cytune Pharma SAS, a French biotechnology company focused on developing novel immunotherapies for the treatment of cancer, announced the closing of a …See details»
CytunePharma - Contacts, Employees, Board Members, Advisors
Cytune’s goal is to turn novel concepts into best-in class immunotherapeutics restoring and activating the immune system to fight cancer.See details»
Science - Sotio
More than 20 of our scientists closely cooperate with colleagues from SOTIO affiliated or partner companies, Cytune Pharma and NBE-Therapeutics, which also develop therapies focused …See details»
David Béchard - Founder, President, CEO, and CSO
Primary Organization . CytunePharma . Location Paris, Ile-de-France, France; ... Gender Male; LinkedIn View on LinkedIn ; David Béchard is the Founder, President, CEO, and CSO at …See details»